Payment overview · 2025
General Payments
$545.47
20 reported records · 11 companies
Healthcare provider profile · identity verified
Kimberly E Pickens, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · THOMASVILLE, GA · NPI 1437478047
Verified facts
What the public records show
CMS Open Payments records show Kimberly E Pickens, M.D. received $545.47 in general payments during 2025 across 20 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 631 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $121.18 | 22.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.47 | 16.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.18 | 14.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.05 | 11.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $41.44 | 7.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.09 | 7.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.85 | 5.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.94 | 4.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.93 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.75 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.59 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $545.47 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $121.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.47 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.18 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.71 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $60.05 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.09 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
159 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
631 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1012 | 177 |
| Gabapentin | Gabapentin | 673 | 129 |
| Eliquis | Apixaban | 631 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 98 |
| Furosemide | Furosemide | 425 | 80 |
| Nifedipine Er | Nifedipine | 424 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 72 |
| Farxiga | Dapagliflozin Propanediol | 337 | 39 |
| Metformin Hcl | Metformin Hcl | 315 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 313 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 309 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 308 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 39 |
| Potassium Chloride | Potassium Chloride | 265 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 251 | 39 |
| Donepezil Hcl | Donepezil Hcl | 246 | 38 |
| Famotidine | Famotidine | 244 | 48 |
| Trazodone Hcl | Trazodone Hcl | 244 | 41 |
| Sertraline Hcl | Sertraline Hcl | 237 | 32 |
| Mirtazapine | Mirtazapine | 234 | 46 |
| Carvedilol | Carvedilol | 223 | 41 |
| Omeprazole | Omeprazole | 219 | 51 |
| Tramadol Hcl | Tramadol Hcl | 212 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 43 |
| Lisinopril | Lisinopril | 197 | 38 |
| Atenolol | Atenolol | 193 | 16 |
| Chlorthalidone | Chlorthalidone | 192 | 43 |
| Losartan Potassium | Losartan Potassium | 187 | 51 |
| Montelukast Sodium | Montelukast Sodium | 181 | 29 |
| Levetiracetam | Levetiracetam | 177 | 26 |
| Ozempic | Semaglutide | 175 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 170 | 39 |
| Linzess | Linaclotide | 159 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 22 |
| Entresto | Sacubitril/Valsartan | 148 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 145 | 45 |
| Myrbetriq | Mirabegron | 141 | 11 |
| Buspirone Hcl | Buspirone Hcl | 139 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 27 |
| Lorazepam | Lorazepam | 129 | 50 |
| Risperidone | Risperidone | 128 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 123 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 24 |
| Bumetanide | Bumetanide | 98 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 19 |
| Baclofen | Baclofen | 94 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 94 | 22 |
| Torsemide | Torsemide | 94 | 20 |
| Memantine Hcl | Memantine Hcl | 92 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 19 |
| Pregabalin | Pregabalin | 87 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 16 |
| Allopurinol | Allopurinol | 76 | 17 |
| Clonazepam | Clonazepam | 76 | suppressed |
| Spironolactone | Spironolactone | 75 | 16 |
| Simvastatin | Simvastatin | 74 | 14 |
| Finasteride | Finasteride | 73 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 15 |
| Jardiance | Empagliflozin | 70 | 17 |
| Mounjaro | Tirzepatide | 70 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 14 |
| Metformin Hcl Er | Metformin Hcl | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 12 |
| Glimepiride | Glimepiride | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 35 |
| Lubiprostone | Lubiprostone | 50 | 11 |
| Olanzapine | Olanzapine | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | suppressed |
| Prednisone | Prednisone | 43 | 22 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Levemir | Insulin Detemir | 39 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 19 |
| Nystatin | Nystatin | 37 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 16 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 19 |
| Meloxicam | Meloxicam | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 11 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Metolazone | Metolazone | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 12 |
| Cefdinir | Cefdinir | 25 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Mupirocin | Mupirocin | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | 11 |
| Methimazole | Methimazole | 16 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 13 |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $545.47 · 20 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, IBSRELA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error